Abstract:Background: Tumor lymphangiogenesis plays an important role in promoting growth and metastasis of tumors, but no antilymphangiogenic agent is used clinically. Based on the effect of norcantharidin (NCTD) on lymphangiogenesis of human lymphatic endothelial cells (LECs), we firstly investigated the antilymphangiogenic activity of NCTD as a tumor lymphangiogenic inhibitor for human colonic adenocarcinomas (HCACs).Methods: In vivo and in vitro experiments to determine the effects of NCTD on tumor growth and lymphangiogenesis of the in-situ colonic xenografts in nude mice, and lymphatic tube formation of the three-dimensional (3-D) of the co-culture system of HCAC HT-29 cells and LECs were done. Proliferation, apoptosis, migration, invasion, Ki-67, Bcl-2 and cell cycle of LECs and the co-culture system in vitro were respectively determined. Streparidin-peroxidase staining, SABC, western blotting and RT-PCR were respectively used to examine the expression of LYVE-1, D2-40, CK20 (including their LMVD), and VEGF-A, VEGF-C, VEGF-D, VEGFR-2 and VEGFR-3 in vitro and in vivo.Results: NCTD inhibited tumor growth and lymphangiogenesis of the in-situ colonic xenografts in vivo, and these observations were confirmed by facts that lymphatic tube formation, proliferation, apoptosis, migration, invasion, S-phase cell cycle, and Ki-67 and Bcl-2 expression in vitro, and LYVE-1, D2-40, CK20 expression and their LMVD in vitro and in vivo were inhibited and affected. Furthermore, the expression of VEGF-A, VEGF-C, VEGF-D, VEGFR-2 and VEGFR-3 at protein/mRNA levels in the process of lymphatic tube formation in vitro and tumor lymphangiogenesis in vivo was downregulated; NCTD in combination with mF4-31C1 or Sorafenib enhanced these effects.Conclusions: NCTD inhibits tumor growth and lymphangiogenesis of HCACs through "multi-points priming" mechanisms i.e. affecting related malignant phenotypes, inhibiting Ki-67 and Bcl-2 expression, inducing S-phase cell cycle arrest, and directly or indirectly downregulating VEGF-A,-C,-D/VEGFR-2,-3 signaling pathways. The present finding strongly suggests that NCTD could serve as a potential antilymphangiogenic agent for tumor lymphangiogenesis and is of importance to explore NCTD is used for antitumor metastatic comprehensive therapy for HCACs.

Norcantharidin Facilitates LPS-mediated Immune Responses by Up-Regulation of AKT/NF-κB Signaling in Macrophages.

Activated niacin receptor HCA2 inhibits chemoattractant-mediated macrophage migration via Gβγ/PKC/ERK1/2 pathway and heterologous receptor desensitization

Norcantharidin Blocks Wnt/β-catenin Signaling Via Promoter Demethylation of WIF-1 in Glioma.

Activated Niacin Receptor Hca2 Inhibits Chemoattractant-Mediated Macrophage Migration Via G Beta Gamma/Pkc/Erk1/2 Pathway And Heterologous Receptor Desensitization

Norcantharidin Ameliorates Proteinuria, Associated Tubulointerstitial Inflammation and Fibrosis in Protein Overload Nephropathy

LC–MS-based quantitation of proteomic changes induced by Norcantharidin in MTB-Treated macrophages

Cantharidin analogue alleviates dextran sulfate sodium-induced colitis in mice by inhibiting the activation of NF-κB signaling

Cantharidin Exerts Anti-Hepatocellular Carcinoma by Mir-214 Modulating Macrophage Polarization

Norcantharidin Inhibits Wnt Signal Pathway Via Promoter Demethylation of WIF-1 in Human Non-Small Cell Lung Cancer.

Norcantharidin Sensitizes Colorectal Cancer Cells to Radiotherapy via Reactive Oxygen Species–DRP1-Mediated Mitochondrial Damage

Norcantharidin Triggers Apoptotic Cell Death in Non-Small Cell Lung Cancer Via a Mitophagy-Mediated Autophagy Pathway

Norcantharidin Modulates Development of Dendritic Cells and Prolongs Skin Allograft Survival

Norcantharidin Induced Du145 Cell Apoptosis Through Ros-Mediated Mitochondrial Dysfunction and Energy Depletion

Norcantharidin Suppresses YD-15 Cell Invasion Through Inhibition of FAK/Paxillin and F-Actin Reorganization

Downregulation of hepcidin by norcantharidin in macrophage

Norcantharidin ameliorates the development of murine lupus via inhibiting the generation of IL-17 producing cells

A Potential Small-Molecule Synthetic Antilymphangiogenic Agent Norcantharidin Inhibits Tumor Growth and Lymphangiogenesis of Human Colonic Adenocarcinomas Through Blocking Vegf-A,-C,-D/Vegfr-2,-3 "Multi-Points Priming" Mechanisms in Vitro and in Vivo

Norcantharidin Suppresses Colon Cancer Cell Epithelial-Mesenchymal Transition by Inhibiting the αvβ6-ERK-Ets1 Signaling Pathway

Norcantharidin Ameliorates Estrogen Deficient-Mediated Bone Loss by Attenuating the Activation of Extracellular Signal-Regulated Kinase/ros/nlrp3 Inflammasome Signaling.

Norcantharidin (NCTD) induces mitochondria mediated apoptosis in human HepG2 cells

Involvement of Mitochondrial Pathway in NCTD-induced Cytotoxicity in Human Hepg2 Cells.